Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Neoadjuvant Pembrolizumab-Based Combination Immunotherapy in the Treatment of Early Stage Non-Small Cell Lung Cancer

NCT04061590 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT04061590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04061590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Neoadjuvant Pembrolizumab-Based Combination Immunotherapy in the Treatment of Early Stage Non-Small Cell Lung Cancer
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Withdrawn
Start date
May 29, 2020
Completion date
August 31, 2023
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung non-small cell carcinoma, stage i lung cancer ajcc v8, stage ia1 lung cancer ajcc v8, stage ia2 lung cancer ajcc v8, stage ia3 lung cancer ajcc v8, stage ib lung cancer ajcc v8, stage ii lung cancer ajcc v8, stage iia lung cancer ajcc v8, stage iib lung cancer ajcc v8, stage iiia lung cancer ajcc v8